PRJ-1142 NHS South East London CCG Community Denosumab Service for Bromley

Descriptions

NHS South East London Clinical Commissioning Group (SEL CCG) is seeking expressions of interest for the provision of a service for prescribing and administering denosumab (Prolia®) through community-based clinics and domiciliary visits. The service will have in place a Shared Care Agreement with relevant secondary care Trusts. The estimated value (£83,977.03) includes the cost of Denosumab (Prolia®) which will be invoiced to the commissioner at cost-price. The estimated value does not include the cost of phlebotomy and pathology. The Contract will be for 12 months, from 1st May 2022 - 30th April 2023. Please refer to the service specification document for further information on the service. The CCG is seeking to award one contract covering the area of the London Borough of Bromley. Applicants must be currently and actively providing healthcare services in Bromley. The service will accept referrals from secondary care. The service will have in place a Shared Care Agreement (SCA) with south east London secondary care Trusts to detail appropriate transfer of care for the provision of denosumab (Prolia®) in a community setting. The SCA will be provided by the CCG. The service will ensure all required phlebotomy and pathology tests are undertaken two weeks prior to the administration of denosumab (Prolia®), and where indicated will ensure phlebotomy and pathology tests are undertaken after administration of denosumab (Prolia®). The service will issue patients with patient reminder cards and information leaflets for denosumab (Prolia®). The service will liaise with secondary care Trusts to confirm the date of dose administration and to support Trusts to ensure appropriate follow-up or subsequent appointments are booked. The service will liaise with secondary care Trusts for advice and guidance, in particular if the patient is hypocalcaemic or hypersensitive to any of the excipients listed in the Summary of Product Characteristics for denosumab (Prolia®). It is estimated that 337 injections will need to be administered in 2022-23. This activity estimate is subject to variation and will be monitored during the life of the contract by the CCG and Provider. Please refer to the service specification document for further information on the service. Please note that the PIN is being advertised as a call for competition. Interested organisation must express an interest via Pro-contract e-tendering portal. Bidders needs to register on Pro-contract if they are not registered already. This can be done by clicking the below link. https://procontract.due-north.com/Register Once registered, you can express an interest in this project and submit the EOI form by clicking the following link to this specific project: https://procontract.due-north.com/Advert?advertId=21ccdb82-58af-ec11-8113-005056b64545 Please note that any expressions of interests by any other means will not be considered.